Acute pericarditis is inflammation of the pericardium, the thin two-layered sac surrounding the heart, and it is the most common disorder affecting this structure. Most cases are triggered by viral infections or have no identifiable cause, and the hallmark symptom is a sharp chest pain that worsens with breathing or lying flat. The condition is usually self-limiting with proper treatment, but it can recur in a frustrating minority of patients and, in rare cases, lead to serious complications.
What Causes It
In high-income countries, the overwhelming majority of acute pericarditis cases are classified as viral or idiopathic, meaning either a virus is confirmed or, more commonly, no specific cause is found but a viral trigger is presumed. In a large prospective cohort, viral or idiopathic causes accounted for roughly 83% of cases, with connective tissue diseases and pericardial injury syndromes making up about 7%, cancer-related pericarditis about 5%, tuberculosis 4%, and bacterial (purulent) pericarditis under 1%.1PubMed. Risk of constrictive pericarditis after acute pericarditis The geographic context matters: tuberculosis is a much more common cause in parts of sub-Saharan Africa and South Asia than in Europe or North America.
Among viral triggers, a wide range of viruses have been implicated, including enteroviruses, herpesviruses, adenoviruses, and parvovirus B19. In clinical practice, however, most patients never get a specific viral diagnosis because targeted testing is expensive, often inconclusive, and rarely changes the treatment plan. That is why clinicians frequently lump these cases together as “idiopathic.”2PubMed. Acute pericarditis
Autoimmune and systemic inflammatory diseases such as lupus, rheumatoid arthritis, and systemic sclerosis can also inflame the pericardium. In these patients, pericarditis may be the presenting symptom of the underlying condition or a flare during an already-known disease course. There is also a distinct group of causes called post-cardiac injury syndromes, which include pericarditis after a heart attack, after heart surgery, and after invasive cardiac procedures like pacemaker implantation or ablation. These are thought to result from an immune reaction triggered by damage to heart or pericardial tissue.3PubMed. Post-cardiac injury syndromes. An emerging cause of pericardial diseases
How It Feels
The classic symptom is sharp, stabbing chest pain that tends to sit behind the breastbone or on the left side. What usually distinguishes it from a heart attack is its relationship to body position and breathing: the pain typically gets worse when you lie down or take a deep breath, and it improves when you lean forward. Many patients describe the relief of sitting up and hunching slightly forward as immediate and dramatic.
Beyond chest pain, you might experience shortness of breath, a low-grade fever, general fatigue, or a dry cough. Some people feel the pain radiating to the left shoulder or neck, which can be confusing because heart attack pain often follows a similar pattern. A physician listening with a stethoscope may detect a pericardial friction rub, a scratchy, grating sound produced by the inflamed pericardial layers rubbing against each other. This sound is fairly specific to pericarditis and, when present, helps clinch the diagnosis, though it is not always audible and can come and go.
How Doctors Diagnose It
The diagnosis rests on a combination of symptoms, physical examination findings, an electrocardiogram (ECG), and blood tests. You typically need at least two of the following four criteria: characteristic chest pain, a pericardial friction rub, specific ECG changes, or a new or worsening pericardial effusion seen on imaging.
The ECG in acute pericarditis has a recognizable pattern that evolves through stages. In the earliest stage, the tracing usually shows widespread ST-segment elevation and PR-segment depression, with a reciprocal ST depression in one particular lead called aVR.4PubMed. PR depression with multi‑lead ST elevation and ST depression in aVR: Is it always acute pericarditis? In a study of 50 patients with uncomplicated acute pericarditis, 48 showed these classic early-stage changes, and roughly two-thirds later developed T-wave inversions in subsequent stages.5The American Journal of Cardiology. Electrocardiogram in acute pericarditis: Distributions of morphologic and axial changes by stages The diffuse nature of the ST elevation, affecting many leads at once, is a key distinguishing feature from a heart attack, where the changes tend to be localized to specific leads corresponding to one part of the heart.
Blood tests usually show elevated inflammatory markers. Many patients also have a mild rise in troponin, a protein released when heart muscle cells are stressed. When troponin is elevated, it often indicates some involvement of the heart muscle itself, a condition called myopericarditis. One study found that the myopericarditis group tended to be younger and had higher troponin levels but actually lower systemic inflammation compared with patients who had pericarditis alone.6PubMed. Can troponin elevation predict worse prognosis in patients with acute pericarditis? Despite the alarming sound of heart muscle involvement, myopericarditis in young, otherwise healthy patients generally carries a good prognosis.
The Role of Imaging
Echocardiography, essentially an ultrasound of the heart, is the first-line imaging tool. It can detect pericardial effusion, assess whether that fluid is pressing on the heart chambers, and help guide decisions about drainage if needed.7Korean Circulation Journal. Pericardial Effusion and Pericardiocentesis: Role of Echocardiography A structured echocardiographic approach evaluates the quantity and quality of pericardial fluid, whether any heart chambers are collapsing under pressure, and how the breathing cycle affects blood flow through the heart, all of which help determine whether a simple effusion is becoming something more dangerous.8PubMed Central. Echocardiographic Evaluation of Pericardial Effusion and Cardiac Tamponade
When the clinical picture is unclear or a complication like constrictive pericarditis is suspected, cardiac MRI and CT become valuable. Cardiac MRI is particularly good at detecting pericardial inflammation by showing enhancement of the pericardium after a contrast agent is injected, a finding that echocardiography cannot reliably detect. These advanced imaging tools have become essential for refining the diagnosis and guiding management in more complex cases.9PubMed Central. Role of Cardiac MRI and CT in Pericarditis and Pericardial Constriction
Standard Treatment
For a typical first episode of acute pericarditis, treatment is straightforward: anti-inflammatory medications plus colchicine. Aspirin or a nonsteroidal anti-inflammatory drug like ibuprofen forms the backbone of therapy, and colchicine is added to reduce the risk of the disease coming back.10PubMed Central. Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis The anti-inflammatory drug is typically tapered over a few weeks as symptoms improve, while colchicine is continued for about three months for a first episode.
Colchicine has become a near-universal addition to therapy thanks to strong trial evidence. The COPE trial showed that adding colchicine to conventional therapy dropped the recurrence rate at 18 months from about 32% to roughly 11%, with a number needed to treat of five.11PubMed. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial The later ICAP trial confirmed these results: colchicine cut symptom persistence at 72 hours roughly in half, reduced the number of recurrences per patient, and even lowered hospitalization rates.12PubMed. A randomized trial of colchicine for acute pericarditis Few treatments in cardiology have this strong a track record in preventing recurrence of a specific condition, and the drug is inexpensive and generally well tolerated. Gastrointestinal side effects like diarrhea are the most common complaint.
The Steroid Question
Corticosteroids can rapidly suppress pericardial inflammation, but they come with a significant catch. Evidence suggests that higher doses of prednisone are associated with more side effects, more recurrences, and more hospitalizations. One observational study found that high-dose prednisone carried a hazard ratio of roughly 3.6 for these combined outcomes compared with lower doses, after adjusting for age, sex, and cause.13PubMed. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation The prevailing view for years was that steroids should be avoided whenever possible because they seem to perpetuate a cycle of flare, steroid use, taper, and flare again.
More recent data has added nuance. One study following acute pericarditis patients for a median of about two years found that low-dose corticosteroids did not act as an independent risk factor for recurrence, suggesting they may be a reasonable option when aspirin, NSAIDs, or colchicine cannot be used or have failed.14PubMed Central. Corticosteroids for Acute and Recurrent Idiopathic Pericarditis: Unexpected Evidences The key seems to be dose: low doses with very gradual tapering may avoid the rebound effect that high-dose regimens trigger. Steroids remain second-line therapy, reserved for patients with genuine contraindications to first-line drugs or for cases with an underlying autoimmune disease that demands corticosteroid treatment on its own merits.
When It Keeps Coming Back
Recurrence is the most common and frustrating complication of acute pericarditis. Even with colchicine added to first-line therapy, somewhere between 15% and 30% of patients experience at least one recurrence. For those who recur, subsequent episodes become increasingly likely, creating a pattern that can stretch over months or years. Recurrent pericarditis is not just a medical nuisance; it disrupts daily life, leads to repeated emergency visits, and often causes significant anxiety about heart health.
Standard management for a first recurrence is essentially the same as for the initial episode: restart or increase anti-inflammatory therapy and ensure colchicine is on board at an adequate dose for at least six months. For the CORE trial, which studied colchicine as first-choice therapy for recurrent pericarditis, the recurrence rate at 18 months dropped from about 51% in the control group to 24% in the colchicine group.15JAMA Internal Medicine. Colchicine as First-Choice Therapy for Recurrent Pericarditis: Results of the CORE Trial
For patients who continue to recur despite colchicine, or who become dependent on steroids to control symptoms, a newer class of drugs targeting interleukin-1 has changed the landscape. Two medications, anakinra and rilonacept, block a key inflammatory signaling molecule involved in the pericardial inflammation loop. In a phase 3 trial, rilonacept was remarkably effective: only about 7% of patients on the drug experienced a recurrence during the study period compared with 74% on placebo.16PubMed. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis A systematic review and meta-analysis confirmed that both anakinra and rilonacept are beneficial in patients with refractory, steroid-dependent disease.17PubMed Central. Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis These drugs are expensive and given by injection, so they are reserved for the toughest cases, but they have genuinely transformed outcomes for patients who previously had no good options beyond chronic steroids.18PubMed Central. Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors
The Heart Attack Lookalike Problem
One of the most clinically significant aspects of acute pericarditis is that it can convincingly mimic a heart attack. Both cause chest pain and ST-segment elevation on the ECG, and in an emergency setting where every minute counts for a true heart attack, the distinction is not always obvious. One institution documented 47 cases over 13 years where myopericarditis was initially misdiagnosed as a heart attack. Nine of those patients received clot-busting thrombolytic therapy before the correct diagnosis was made.19European Heart Journal. Outcome after thrombolytic therapy of nine cases of myopericarditis misdiagnosed as myocardial infarction Fortunately, in that series, no severe complications resulted from the unnecessary treatment, though the potential for bleeding complications makes this misdiagnosis more than a harmless inconvenience.
Several clues help tell the two apart. Pericarditis pain is typically sharp, pleuritic (worsened by breathing), and positional, while heart attack pain is usually a deeper pressure or squeezing sensation unrelated to breathing. On the ECG, pericarditis produces diffuse ST elevation across many leads and often PR depression, while a heart attack produces ST elevation localized to a specific coronary territory with reciprocal depression in the opposite leads. Patient demographics also help: pericarditis tends to strike younger, otherwise healthy individuals, while heart attacks are more common in older patients with cardiovascular risk factors. Still, none of these distinguishing features is absolute, and emergency departments rightly err on the side of treating for a heart attack when there is genuine uncertainty.
Exercise and Getting Back to Normal
If you are used to being active, the recovery period can feel surprisingly restrictive. Both American and European guidelines recommend avoiding competitive sports and strenuous exercise during active pericarditis and for a period after symptoms resolve, typically at least three months for athletes. The reasoning is that while the exact mechanism by which exercise might worsen pericarditis remains uncertain, exertion during active pericardial or myocardial inflammation could theoretically provoke arrhythmias or worsen the inflammatory process.20PubMed Central. The Impact of Physical Activity on Pericarditis
In practice, the return-to-exercise timeline depends on several factors: whether the myocardium was involved, whether inflammatory markers have normalized, whether there is any remaining effusion, and whether you are symptom-free. Most clinicians use a combination of blood tests, ECG normalization, and imaging to clear a patient for progressive return to activity. Gentle walking is generally fine once acute symptoms settle, but high-intensity exercise, weight lifting, and competitive sports need a longer waiting period. For recreational exercisers who had uncomplicated pericarditis without myocardial involvement, the timeline is typically shorter than for competitive athletes, though your doctor will individualize the recommendation.
Pericarditis in Pregnancy
Managing pericarditis during pregnancy presents a genuine challenge because several standard medications carry risks for the developing fetus. No formal guidelines exist for the optimal approach to diagnosis or treatment in pregnant patients.21PubMed. Noninvasive Multimodality Imaging and Special Treatment Considerations for Pericarditis in Pregnancy Aspirin at low doses is generally considered safe through most of pregnancy, but high-dose aspirin raises concerns, particularly near delivery. NSAIDs like ibuprofen are typically avoided after 20 weeks of gestation because of potential effects on the fetal kidneys and a structure in the fetal heart called the ductus arteriosus. Colchicine lacks robust safety data in pregnancy, so many clinicians avoid it despite its effectiveness.
The largest reported case series followed six pregnancies in women with recurrent idiopathic pericarditis. Four were treated with aspirin at moderate doses, with aspirin being gradually stopped at 20 weeks in three cases, and all received low-to-moderate dose prednisone. Five of the six pregnancies were uneventful. The one complication, a serious pregnancy condition called HELLP syndrome, occurred in the patient who continued high-dose aspirin until delivery, with rapid improvement after delivery. No pericarditis recurrences occurred during any of the pregnancies, though one mother had a recurrence a year after delivery.22International Journal of Cardiology. Pregnancy in idiopathic recurrent pericarditis The small sample size means these findings are more reassuring anecdote than robust guidance, but the overall message is that careful management with adjusted medications can get most patients through pregnancy safely.
Pericarditis in Kidney Disease
Patients with advanced kidney disease represent a distinct population where pericarditis has different causes and requires a different treatment approach. Pericarditis can develop in two contexts here: uremic pericarditis, which occurs when kidney function is severely impaired and toxins build up, and dialysis-associated pericarditis, which can appear even in patients who are already receiving regular dialysis treatment. Both forms carry real risks including cardiac tamponade and constrictive pericarditis.23PubMed Central. Understanding Hemodialysis-Associated Pericarditis: Causes, Symptoms, and Management Strategies
The treatment approach differs from standard pericarditis management. For uremic pericarditis, the primary intervention is initiating or intensifying dialysis rather than simply prescribing anti-inflammatory drugs. Intensive hemodialysis, typically performed daily for five to seven days, is usually needed. These sessions are done without blood-thinning medications to avoid pericardial bleeding, and with minimal fluid removal to prevent dangerously low blood pressure.24PubMed Central. Uremic Pericarditis: A Report of 30 Cases and Review of the Literature Anti-inflammatory medications and colchicine may still play a role alongside intensified dialysis, and in severe cases, drainage of pericardial fluid or even surgical intervention is required. The recognition that kidney-related pericarditis needs this tailored approach is important because applying the standard viral-pericarditis playbook to these patients would miss the underlying problem entirely.
Why the Immune System Keeps Attacking the Pericardium
One of the persistent puzzles in pericarditis research is why some patients develop a single episode that resolves cleanly while others fall into a relapsing pattern. The leading theory involves a self-perpetuating immune response. After an initial injury, whether from a virus, surgery, or some other trigger, the immune system mounts an inflammatory response in the pericardium. In most patients, this response resolves as the trigger clears. But in a subset of people, the immune system seems to become sensitized to the pericardial tissue itself. Research on pericardial fluid has found elevated levels of inflammatory signaling molecules like interleukin-6, interleukin-8, and interferon-gamma within the pericardial space, but not in the patient’s blood, suggesting a localized immune process rather than a body-wide one.25Springer. Cytokine activation in pericardial fluids in different forms of pericarditis
This localized immune activation helps explain both why the condition recurs and why interleukin-1 blockers work so well in refractory cases. It also explains why Dressler syndrome, the post-heart-attack pericarditis first described in the 1950s, behaves the way it does. In Dressler syndrome, heart muscle damage exposes proteins that the immune system had not previously encountered, triggering an autoimmune reaction that inflames the pericardium weeks after the initial heart attack.26III Seven International Medical and Nursing Congress. Post-myocardial infarction pericarditis: Dressler syndrome and its clinical implications The syndrome has become less common in the era of rapid heart-attack treatment, likely because faster restoration of blood flow limits the amount of heart muscle damage and therefore the amount of protein exposed to the immune system. But when it does occur, it follows the same immune-mediated pattern seen in other recurrent pericarditis.
Understanding this immune mechanism has shifted how clinicians think about treatment. Rather than just suppressing symptoms with anti-inflammatory drugs, the goal in recurrent cases is to interrupt the specific immune pathway driving the inflammation. That shift in thinking is what led to the development and testing of the interleukin-1 blockers, which target the exact signaling cascade that keeps the pericardial inflammation alive.